Table 3.

Major non-breast cancer events in the prevention trials

	Endometrial cancer	All other cancer*	Any death	Breast cancer death	Venous thrombolic events†	Cardiovascular events‡	All fractures	Non-vertebral fractures	Vertebral fractures	Cataracts
Marsden	12 vs 5	55 vs 60	54 vs 54	12 vs 9	..	..	..	..	..	..
IBIS-I	19 vs 11	110 vs 113	65 vs 55	10 vs 12	65 vs 43	40 vs 38	229 vs 252	221 vs 244	8 vs 8	76 vs 70
NSABP-P-1	36 vs 15	101 vs 103	59 vs 71	4 vs 6	55 vs 29	90 vs 82	502 vs 539	480 vs 509	22 vs 30	578 vs 513
Italian	..	106 vs 91	36 vs 38	2 vs 2	11 vs 10	14 vs 10	..	..	..	..
MORE/CORE	6 vs 8	112 vs 132	81 vs 84	..	47 vs 25	82 vs 78	353 vs 450	214 vs 225	139 vs 225	275 vs 280
RUTH	21 vs 17	204 vs 203	548 vs 585	2 vs 0	106 vs 73	487 vs 481	529 vs 591	470 vs. 499	59 vs 92	570 vs 561
STAR§ (raloxifene vs tamoxifen)	37 vs 65	354 vs 323	202 vs 236	4 vs 11	154 vs 202	233 vs 220	1272 vs 1364	1195 vs 1299	65 vs 77	603 vs 739
PEARL (0·5 mg vs 0·25 mg vs placebo)	2 vs 2 vs 3	25 vs 20 vs 22	92 vs 73 vs 65	..	48 vs 37 vs 18	47 vs 54 vs 76	359 vs 422 vs 508	203 vs 233 vs 246	156 vs 189 vs 262	320 vs 317 vs 330
GENERATIONS	9 vs 4	74 vs 75	103 vs 98	..	43 vs 17	71 vs 64	426 vs 508	316 vs 327	110 vs 181	382 vs 400
All events	105 vs 63	787 vs 799	1038 vs 1050	30 vs 29	375 vs 215	831 vs 829	2398 vs 2848	1904 vs 2050	494 vs 798	2201 vs 2154
HR or OR (95% CI)	HR 1·56 (1·13–2·14)	HR 0·98 (0·89–1·08)	HR 0·98 (0·90–1·06)	HR 1·03 (0·55–1·92)	OR 1·73 (1·47–2·05)	OR 0·99 (0·91–1·09)	OR 0·85 (0·80–0·89)	OR 0·93 (0·87–0·99)	OR 0·66 (0·59–0·73)	OR 1·01 (0·95–1·06)

Data are number of patients for selective oestrogen receptor modulator versus vs placebo, unless otherwise indicated. HR=hazard ratio. OR=odds ratio

^*Excluding endometrial cancer.

^†Including deep vein thrombosis, pulmonary embolism, retinal thrombosis; excluding superficial thrombosis.

^‡Including myocardial infarction, cerebrovascular accident, and transient ischaemic accident.

^§STAR data not included for overall effect.